![]() |
产地 | 中国 |
品牌 | 爱必信(absin) |
货号 | abs819615 |
用途 | 见爱必信官网 |
英文名称 | 见爱必信官网 |
包装规格 | 5mg,5mg,25mg,25mg |
纯度 | 98%% |
CAS编号 | 133208-93-2 |
别名 | NO-1886; |
是否进口 | 否 |
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Ibrolipim 产品别名:见爱必信官网 英文别名:Ibrolipim 靶点: CAS:133208-93-2 纯度:98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述:Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects. 溶解性:Soluble in DMSO (≥20 mg/ml). 体外研究:
Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at translational levels in a dose-dependent and time-dependent manner . 体内研究:Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue.
产品信息订购:
|